VEGF and SEMA4D have synergistic effects on the promotion of angiogenesis in epithelial ovarian cancer

• Autorzy: Chen Y. , Zhang L. , Liu W. , Wang K.
• Języki publikacji: EN

Abstrakty

EN

Background: Anti-angiogenesis therapy that targets VEGF is one of the important treatment strategies in advanced ovarian cancer. However, depending on the pharmaceutical agent, treatment can have undesirable side effects. SEMA4D has recently gained interest for its role in promoting angiogenesis. Here, we try to further understand the mechanism by which SEMA4D promotes angiogenesis in ovarian cancer. Methods: Correlation and western blot assaya were used to detect the relationship between VEGF and SEMA4D in clinical tissues and cells. Vasculogenic mimicry and transwell migration analyses were used to detect the roles of VEGF, SEMA4D and plexin-B1 on vasculogenic mimicry and migration. Vascular density and SEMA4D expression was determined using immunofluorescence staining in clinical tissues of EOC. Western blot was used to detect the expressions of CD31, MMP2 and VE-cadherin. We also analyzed the relationship between VEGF-SEMA4D and malignant tumor prognosis. Results: We found that knockdown of VEGF could suppress SEMA4D expression and that the expressions of VEGF and SEMA4D have a positive correlation in EOC cancer tissues. Vasculogenic mimicry and transwell migration analyses showed that SEMA4D and VEGF have a synergistic effect on the promotion of angiogenesis in A2780 and HUVEC cells. Soluble SEMA4D (sSEMA4D) could promote VM and migration in A2780 and HUVEC cells via the SEMA4D/plexin-B1 pathway, but the effect was not noted in stably transfected shR-plexin-B1 cells. In clinical tissues of EOC, the vascular density and SEMA4D/plexin-B1 expression were higher. When VEGF, SEMA4D and plexin-B1 was knocked down, the expression of CD31, MMP2 and VE-cadherin, which are the markers and initiators of angiogenesis and the epithelial–mesenchymal transition (EMT) process were reduced. VEGF and SEMA4D had a positive correlation with the malignant degree of ovarian cancer, and SEMA4D can serve as an independent prognostic factor. Conclusions: VEGF and SEMA4D have synergistic effects on the promotion of angiogenesis in epithelial ovarian cancer. Targeting VEGF and the SEMA4D signaling pathway could be important for the therapy for EOC.

• Wydawca: -
• Czasopismo: Cellular and Molecular Biology Letters
• Rocznik: 2018
• Tom: 23
• Opis fizyczny: p.1-12,fig.,ref.

Twórcy

autor

Chen Y.

• Department of Gynecologic Oncology, Tianjin Medical University Cancer Institute and Hospital, Huanhuxi Road, Hexi District, Tianjin 300060, China
• Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China

autor

Zhang L.

• Department of Gynecologic Oncology, Tianjin Medical University Cancer Institute and Hospital, Huanhuxi Road, Hexi District, Tianjin 300060, China
• Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China

autor

Liu W.

• Department of Gynecologic Oncology, Tianjin Medical University Cancer Institute and Hospital, Huanhuxi Road, Hexi District, Tianjin 300060, China
• Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China

autor

Wang K.

• Department of Gynecologic Oncology, Tianjin Medical University Cancer Institute and Hospital, Huanhuxi Road, Hexi District, Tianjin 300060, China
• Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China

Bibliografia

• 1. Bookman MA. Should studies of maintenance therapy be maintained in women with ovarian cancer? J Gynecol Oncol. 2013;24:105–7.
• 2. Folkman J. Incipient angiogenesis. Natl Cancer Inst. 2000;92:94–5.
• 3. Gianni-Barrera R, Trani M, Reginato S, Banfi A. To sprout or to split? VEGF, notch and vascular morphogenesis. Biochem Soc Trans. 2011;39:1644–8. https://doi.org/10.1042/BST20110650.
• 4. Scartozzi M, et al. VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study. Int J Cancer. 2014;135:1247–56.
• 5. Folkman J, et al. Isolation of a tumor factor responsible for angiogenesis. J ExpMed. 1971;133(2):275–88.
• 6. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182–6.
• 7. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249–57.
• 8. Carmeliet P, Baes M. Metabolism and therapeutic angiogenesis. N Engl J Med. 2008;358(23):2511–2.
• 9. Burstein HJ, Schwartz RS. Molecular origins of cancer. N Engl J Med. 2008;358(5):527.
• 10. Avail-Lundqvist EH, et al. The impact of tumour angiogenesis, p53 overexpression and proliferative activity (M1B-1) on survival in squamous cervical carcinoma. Eur J Cancer. 1997;33(11):1799–804.
• 11. Sitohy B, Nagy JA, Dvorak HF. Anti-VEGF/VEGFR therapy for cancer: reassessing the target. Cancer Res. 2012;72:1909–14.
• 12. Burger RA, Brady MF, Bookman MA. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a gynecologic oncology study. J Clin Oncol. 2010;28(Suppl):abstr LBA1.
• 13. Kristensen G, Perren T, Qian W. Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. J Clin Oncol. 2011;29(Suppl):abstr LBA5006.
• 14. Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, Chorianopoulos E, Liesenborghs L, Koch M, De Mol M, Autiero M, Wyns S, Plaisance S, Moons L, van Rooijen N, Giacca M, Stassen JM, Dewerchin M, Collen D, Carmeliet P. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell. 2007;131:463–75.
• 15. Kong-Beltran M, Stamos J, Wickramasinghe D. The Sema domain of met is necessary for receptor dimerization and activation. Cancer Cell. 2004;6:75–84.
• 16. Serini G, Maione F, Giraudo E, Bussolino F. Semaphorins and tumor angiogenesis. Angiogenesis. 2009;12:187–93.
• 17. Gu C, Giraudo E. The role of semaphorins and their receptors in vascular development and cancer. Exp Cell Res. 2013. [Epub ahead of print].
• 18. Basile JR, Castilho RM, Williams VP, Gutkind JS. Semaphorin 4D provides a link between axon guidance processes and tumor-induced angiogenesis. Proc Natl Acad Sci U S A. 2006;103:9017–22.
• 19. Basile JR, Barac A, Zhu T, Guan KL, Gutkind JS. Class IV semaphorins promote angiogenesis by stimulating rhoinitiated pathways through plexin-B. Cancer Res. 2004;64:5212–24.
• 20. Conrotto P, Valdembri D, Corso S, Serini G, Tamagnone L, Comoglio PM, Bussolino F, Giordano S. Sema4D induces angiogenesis through met recruitment by Plexin B1. Blood. 2005;105:4321–9.
• 21. Orre M, Rogers PA. VEGF, VEGFR-1, VEGFR-2, microvessel density and endothelial cell proliferation in tumours of the ovary. Int J Cancer. 1999;84(2):101–8.
• 22. Takeshita N, Hasegawa M, Sasaki K. In vivo expression and regulation of genes associated with vascularization during early response of sutures to tensile force. J Bone Miner Metab. 2016;29.
• 23. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe’er J, Trent JM, Meltzer PS, Hendrix MJ. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol. 1999;155:739–52.
• 24. Sierra JR, Corso S, Caione L, et al. Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages. J Exp Med. 2008;205:1673–85.
• 25. Sun T, Zhao N, Zhao XL, Gu Q, Zhang SW, Che N, Wang XH, Du J, Liu YX, Sun BC. Expression and functional significance of Twist1 in hepatocellular carcinoma: its role in vasculogenic mimicry. Hepatology. 2010;51(2):545–56.

Identyfikatory

DOI

10.1186/s11658-017-0058-9